Skip main navigation

Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase

21 April 2016

Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease.

Proteon Therapeutics Inc. (Nasdaq:PRTO), a longstanding client of Biopta, is developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. Proteon today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD). The ex vivo study demonstrated that a single treatment of vonapanitase following angioplasty of excised atherosclerotic human tibial arteries altered artery compliance. Increased compliance is known to correlate with arterial dilation.

The study, titled Recombinant Human Elastase Alters the Compliance of Atherosclerotic Tibial Arteries After Ex Vivo Angioplasty, was published in the Journal of Cardiovascular Pharmacology. Proteon's Senior Vice President and Chief Medical Officer, Steven Burke, M.D., is the senior author of the published manuscript. Dr Karen Bingham and Dr Emma Moss of Biopta were co-authors.

Subscribe to receive updates